Compare IBTA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBTA | CERT |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.3M | 860.9M |
| IPO Year | 2024 | 2020 |
| Metric | IBTA | CERT |
|---|---|---|
| Price | $35.95 | $6.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $28.50 | $11.67 |
| AVG Volume (30 Days) | 115.9K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | $342,389,000.00 | ★ $418,838,000.00 |
| Revenue This Year | $2.02 | $4.18 |
| Revenue Next Year | $8.96 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $19.10 | $5.19 |
| 52 Week High | $56.60 | $13.88 |
| Indicator | IBTA | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 55.41 |
| Support Level | $34.61 | $5.93 |
| Resistance Level | N/A | $6.48 |
| Average True Range (ATR) | 1.33 | 0.28 |
| MACD | -0.24 | 0.04 |
| Stochastic Oscillator | 22.64 | 76.87 |
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.